Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793507191 ◽

2015 ◽

Author(s):

Greg Bociek

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793516889 ◽

2016 ◽

Author(s):

John Wingard ◽

Maxim Norkin

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793511115 ◽

2015 ◽

Author(s):

Won Seog Kim

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793517166 ◽

2016 ◽

Author(s):

Stephen Ansell

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

The Lancet ◽

10.1016/s0140-6736(10)61424-9 ◽

2010 ◽

Vol 376 (9758) ◽

pp. 2075-2085 ◽

Cited By ~ 578

Author(s):

Michele Cavo ◽

Paola Tacchetti ◽

Francesca Patriarca ◽

Maria Teresa Petrucci ◽

Lucia Pantani ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Cell Transplantation ◽

Induction Therapy ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Phase 3

Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(14)00022-2 ◽

2014 ◽

Vol 1 (3) ◽

pp. e112-e119 ◽

Cited By ~ 6

Author(s):

Anna Kalff ◽

Nola Kennedy ◽

Angela Smiley ◽

H Miles Prince ◽

Andrew W Roberts ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Cell Transplantation ◽

Final Analysis ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70245-1 ◽

2014 ◽

Vol 15 (8) ◽

pp. 874-885 ◽

Cited By ~ 93

Author(s):

Gordon Cook ◽

Cathy Williams ◽

Julia M Brown ◽

David A Cairns ◽

Jamie Cavenagh ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

High Dose Chemotherapy ◽

High Dose ◽

Consolidation Therapy ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Hematological Oncology ◽

10.1002/hon.2897 ◽

2021 ◽

Author(s):

Olga Meltem Akay ◽

Murat Ozbalak ◽

Mustafa Pehlivan ◽

Birol Yildiz ◽

Ant Uzay ◽

...

Keyword(s):

Stem Cell ◽

Retrospective Study ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30140-0 ◽

2017 ◽

Vol 4 (9) ◽

pp. e431-e442 ◽

Cited By ~ 63

Author(s):

Sarah A Holstein ◽

Sin-Ho Jung ◽

Paul G Richardson ◽

Craig C Hofmeister ◽

David D Hurd ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Cell Transplantation ◽

Phase 3 ◽

Double Blind

Poster: HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01484-1 ◽

2021 ◽

Vol 21 ◽

pp. S236

Author(s):

Murat Ozbalak ◽

Olga Meltem Akay ◽

Mustafa Pehlivan ◽

Birol Yildiz ◽

Ant Uzay ◽

...

Keyword(s):

Stem Cell ◽

Retrospective Study ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy